Kurzfassung des Positionspapiers der DGAI - In-vitro-Diagnostik allergischer Erkrankungen

Zusammenfassung

Parallel mit der Entwicklung neuer Erkenntnisse zur Immunpathogenese allergischer Erkrankungen fanden in den letzten Jahren vielfältige Weiterentwicklungen in der In-vitro-Allergiediagnostik statt. Zum einen sind die Allergene, die im Rahmen der Immuntests eingesetzt werden, besser charakterisiert und standardisiert, zum anderen wurden neue Parameter entwickelt, deren Nutzen im Bereich der Prädiktion, Diagnostik und des Therapieverlaufes evaluiert werden muss. Die Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAI) hat deshalb eine Arbeitsgruppe gebildet, die ein Positionspapier zur In-vitro-Allergiediagnostik erarbeitet hat. Dieses Positionspapier ist bereits im letzten Jahr erschienen (Allergojournal 2002; 11: 492-506). Für diese Ausgabe des klinikarzt wurde eine für den klinischen Alltag relevante Kurzfassung erarbeitet, welche die wesentlichen und praxisrelevanten Aspekte der In-vitro-Allergiediagnostik zusammenfasst.

Summary

In parallel with the acquirement of new knowledge on the immunopathogenesis of allergic diseases, the past few years have seen numerous further advances in the in vitro diagnosis of allergies. Not only has the characterization of the allergens employed for immune tests been improved and standardized, but also new parameters have been developed, the utility of which in the areas of prediction, diagnosis and treatment monitoring still has to be evaluated. In the light of these developments, the „German Society for Allergology and Clinical Immunology” (Deutsche Gesellschaft für Allergologie und Klinische Immunologie, DGAI) set up a working group which has generated a position paper on the in vitro diagnosis of allergic disorders. This position paper was published last year (Allergojournal 2002; 11: 492-506). For the present issue of klinikarzt, a summary of the major and practice-relevant aspects of in vitro allergy diagnosis is presented.

Key Words

allergene - IgE - IgG4 - lymphozyte stimulation test - eosinophil cationic protein (ECP)

Literatur

• 1 EAACI Position Paper Immunotherapy.  Allergy Suppl. 1993;  48 63-70
• 2 Bellinghausen I, Enk AH, Mohamadzadeh M. et al. . Epidermal cells enhance interleukin 4 and immunoglobulin E production after stimulation with protein allergen.  J Invest Dermatol. 1996;  107 582-588
• 3 Bousquet J. Report of WHO-meeting on the future of immunotherapy.  Allergie-Symposium Berlin 20.-22. Juni. 1997;  46-47
• 4 Büchner K, Siepe M. Nutzen der Hyposensibilisierung unter wirtschaftlichen Aspekten.  Allergo Journal. 1995;  4 156-163
• 5 Creticos PS, VanMetre TE, Mardiney MR, et al. Dose response of IgE and IgG antibodies during ragweed immunotherapy.  J Allergy Clin Immunol. 1984;  73 94-104
• 6 Feinberg SM, Foran EL, Lichtenstein MR. Oral therapy in ragweed pollinosis, a comparative study.  J Americ Med Assoc. 1940;  115 23-29
• 7 Gleich GJ, Zimmermann EM, Henderson LL, Yunginger JW. Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study.  J Allergy Clin Immunol. 1982;  70 261-271
• 8 Grammer LC, Shaughnessy MA, Finkle. et al. . A double-blind placebo-controlled trial of polymerized whole grass administered in an accelerated dosage schedule for immunotherapy of grass pollinosis.  J Allergy Clin Immunol. 1986;  78 1180-1184
• 9 Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects.  J Allergy Clin Immunol. 1993;  91 709-722
• 10 Horak F, Jäger S, Berger U. et al. . Sublingual birch pollen extract for IT (SLIT).  Allergy Suppl. 1995;  50 279
• 11 Jorde W. Sublinguale und orale Hyposensibilisierung.  Allergologie. 1996;  19 563-592
• 12 Jutel M, Pichler WJ, Skrbic D. et al. . Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures.  J Immunol. 1995;  154 4187-4194
• 13 Kesarwala HH, Maccia C, Amaram N. et al. . Suppressor T cells and soluble suppressor factors in allergy: effect of immunotherapy.  Clin Allergy. 1984;  14 519-524
• 14 Klimek L, Reske-Kunz AB, Saloga J. Spezifische Immuntherapie - Hyposensibilisierung.  Stuttgart: Georg Thieme Verlag. 1999; 
• 15 Klimek L, Wolf H, Mewes T. et al. . The effect of short-term immunotherapy with molecular standardized grass and rye allergens on eosinophil cationic protein and tryptase in nasal secretions.  J Allergy Clin Immunol. 1999;  103 47-53
• 16 Lin LM, Mac CG Pherson. Antigen acquisition by dendritic cells: intestinal dendritic cells acquire antigen administered orally and can prime naive T cells in vivo.  J Exp Med. 1993;  177 1299-1305
• 17 McMenamin C, Schon M Hegrad, Oliver J. et al. . Regulation of IgE responses to inhaled antigens: cellular mechanisms underlying allergic sensitization versus tolerance induction.  Int Arch Allergy Appl Immunol. 1991;  94 78-82
• 18 Noon L. Prophylactic inoculation of hay fever.  Lancet. 1911;  1 572-573
• 19 Norman PS. Immunotherapy for nasal allergy (symposium).  J Allergy Clin Immunol. 1988;  81 992-996
• 20 Ohman JL. Allergen immunotherapy in asthma: evidence for efficacy.  J Allergy Clin Immunol. 1989;  84 133-140
• 21 Passalacqua G, Canonica GW. Alternative routes for allergen-specific immunotherapy.  J Invest Allergol Clin Immunol. 1996;  6 81-87
• 22 Pichler CE, Maryuardsen A, Sparholt S. et al. . Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae in decreased bronchial hyperreactivity.  Allergy. 1997;  52 274-283
• 23 Rocklin RE, Pence H, Kaplan H, Evans R. Cell-mediated immune response of ragweed-sensitive patients to ragweed antigen E: In vitro lymphocyte transformation and elaboration of lymphocyte mediators.  J Clin Invest. 1974;  53 735-744
• 24 Rocklin RE, Sheffer AL, Greineder DK, Melmon KL. Generation of antigen-specific suppressor cells during allergy desensitization.  New Engl J Med. 1980;  302 1213-1219
• 25 Sadan N, Rhyne MB, Mellits ED. et al. . Immunotherapy of pollinosis in children. Investigation of the immunologic basis of clinical improvement.  N Engl J Med. 1969;  280 623-627
• 26 Saloga J, Renz H, Lack G. et al. . Development and transfer of immediate cutaneous hypersensitivity in mice exposed to aerosolized antigen.  J Clin Invest. 1993;  91 133-140
• 27 Scadding K, Brostoff J. Low-dose sublingual therapy in patients with allergic rhinitis due to dust mite.  Clin Allergy. 1986;  16 483-491
• 28 Secrist H, Chelen CJ, Wen Y. et al. . Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals.  J Exp Med. 1993;  178 2123-2130
• 29 Subcommittee on Insect Venom Allergy . Position paper. Immunotherapy with hymenoptera venoms.  Allergy. 1993;  48 37-46
• 30 Taudorf E. Oral immunotherapy of adults with allergic rhinoconjunctivitis.  Dan Med Bull. 1992;  39 542-560
• 31 Udall JN, Walker WA. Antigentransport im Darm.  Allergologie. 1984;  7 263-269
• 32 Van MetreTE, Adkinson NF, Kagey-Sobotka A. et al. . Immunotherapy decreases skin sensitivity to ragweed extract: demonstration by midpoint skin test titration.  J Allergy Clin Immunol. 1990;  87 299
• 33 Zenner HP, Baumgarten C, Rasp G. et al. . Short-term immunotherapy: A prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis.  J Allergy Clin Immunol. 1997;  100 23-29
• 34 Mellerup MT, Hahn GW, Poulsen LK, Malling HJ. Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment.  Clin Exp Allergy. 2000;  30 1423-1429

Anschrift für die Verfasser